Bristol Myers Squibb Opts for Veeva Vault CRM to Enhance Patient Interaction
Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has officially committed to adopting Veeva Vault CRM, a cutting-edge customer relationship management solution. This strategic decision was announced on September 22, 2025, emphasizing the company's dedication to leveraging technology to deepen its relationships with healthcare professionals and ultimately enhance patient outcomes.
Greg Meyers, the head of digital strategy and technology at Bristol Myers Squibb, commented on the transformative capabilities of cutting-edge tech, stating that, "Technology fundamentally changes how we engage with our customers and the patients they serve." This initiative signifies a significant evolution in BMS’s approach to managing its relationships within the healthcare community, aiming to bolster how physicians access vital information about the company's diverse range of innovative therapies.
With Veeva Vault CRM, BMS aims to streamline communication and facilitate better decision-making among healthcare professionals. The CRM will utilize sophisticated AI features to embed intelligent agents throughout the customer journey, improving interactions from how doctors receive crucial product information to their ongoing engagement with BMS’s field representatives. This integration reflects the company's forward-thinking strategy to provide timely and relevant information to professionals, which is more crucial than ever as the complexity of modern medicine increases.
"By incorporating AI at every stage of the customer journey—ranging from how physicians access essential insights about our portfolio, to their interactions with our sales team—Veeva is superbly positioned to support our mission of delivering life-changing therapies to patients globally," Meyers remarked.
Peter Gassner, CEO of Veeva, also expressed enthusiasm regarding the partnership, emphasizing the shared commitment to meeting patient needs. He stated, "We value the trust and partnership and are devoted to assisting Bristol Myers Squibb in providing therapies that improve the lives of patients facing serious illnesses." With Veeva Vault CRM, they are set to offer next-generation CRM capabilities, equipped with embedded AI agents designed to enhance physician engagement and expedite the delivery of appropriate treatments to patients.
The anticipated rollout of Veeva's first AI agents under the Vault CRM system includes applications named Pre-Call Agent, Content Agent, Free Text Agent, and Voice Agent. These innovations are expected to become available by December 2025, representing a significant leap forward in how BMS interacts with healthcare providers.
Veeva Systems has positioned itself as the leading industry cloud provider for life sciences, delivering software solutions, data analytics, and consulting services tailored to the unique needs of this sector. With a commitment to innovation and customer success, Veeva serves over 1,500 clients, including some of the largest biopharmaceutical firms and emerging biotech companies.
The adoption of Veeva Vault CRM is more than just a technological upgrade for Bristol Myers Squibb; it is a strategic move designed to enhance the overall experience for healthcare professionals and, ultimately, improve patient care. By prioritizing the integration of advanced technologies and focusing on meaningful partnerships, BMS exemplifies the dynamic role that technology continues to play in the pharmaceutical industry. As this collaboration unfolds, the potential to revolutionize how treatments are delivered and discussed in clinical settings becomes increasingly apparent, paving the way for innovative healthcare solutions in the future.
Greg Meyers, the head of digital strategy and technology at Bristol Myers Squibb, commented on the transformative capabilities of cutting-edge tech, stating that, "Technology fundamentally changes how we engage with our customers and the patients they serve." This initiative signifies a significant evolution in BMS’s approach to managing its relationships within the healthcare community, aiming to bolster how physicians access vital information about the company's diverse range of innovative therapies.
With Veeva Vault CRM, BMS aims to streamline communication and facilitate better decision-making among healthcare professionals. The CRM will utilize sophisticated AI features to embed intelligent agents throughout the customer journey, improving interactions from how doctors receive crucial product information to their ongoing engagement with BMS’s field representatives. This integration reflects the company's forward-thinking strategy to provide timely and relevant information to professionals, which is more crucial than ever as the complexity of modern medicine increases.
"By incorporating AI at every stage of the customer journey—ranging from how physicians access essential insights about our portfolio, to their interactions with our sales team—Veeva is superbly positioned to support our mission of delivering life-changing therapies to patients globally," Meyers remarked.
Peter Gassner, CEO of Veeva, also expressed enthusiasm regarding the partnership, emphasizing the shared commitment to meeting patient needs. He stated, "We value the trust and partnership and are devoted to assisting Bristol Myers Squibb in providing therapies that improve the lives of patients facing serious illnesses." With Veeva Vault CRM, they are set to offer next-generation CRM capabilities, equipped with embedded AI agents designed to enhance physician engagement and expedite the delivery of appropriate treatments to patients.
The anticipated rollout of Veeva's first AI agents under the Vault CRM system includes applications named Pre-Call Agent, Content Agent, Free Text Agent, and Voice Agent. These innovations are expected to become available by December 2025, representing a significant leap forward in how BMS interacts with healthcare providers.
Veeva Systems has positioned itself as the leading industry cloud provider for life sciences, delivering software solutions, data analytics, and consulting services tailored to the unique needs of this sector. With a commitment to innovation and customer success, Veeva serves over 1,500 clients, including some of the largest biopharmaceutical firms and emerging biotech companies.
The adoption of Veeva Vault CRM is more than just a technological upgrade for Bristol Myers Squibb; it is a strategic move designed to enhance the overall experience for healthcare professionals and, ultimately, improve patient care. By prioritizing the integration of advanced technologies and focusing on meaningful partnerships, BMS exemplifies the dynamic role that technology continues to play in the pharmaceutical industry. As this collaboration unfolds, the potential to revolutionize how treatments are delivered and discussed in clinical settings becomes increasingly apparent, paving the way for innovative healthcare solutions in the future.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.